Histologically proven initial diagnosis of adenocarcinoma of the prostate;
Biochemical relapse of PCa following radical local prostate treatment (radical prostatectomy, primary radiotherapy or radical prostatectomy +/- prostate bed adjuvant/salvage radiotherapy) +/- ADT according to the European Association of Urology (EAU) guidelines 2016 \[18\] or after any salvage therapy if biochemical progression is diagnosed in the context of castration sensitive PCa;
Nodal relapse in the pelvis, extra-regional nodal relapse (M1a), bone metastases (M1b) on Ch-PET/CT or WBMRI with a maximum of 3 lesions;
Serum testosterone level \>50 ng/dl at the time of randomization (castration sensitive PCa)
Eastern Cooperative Oncology Group (ECOG) performance status 0-1;
Age ≥18 years;
Written informed consent signed
You may not be if
Serious concomitant comorbidities or contraindication to SBRT and/or ADT;
Previous invasive cancer (within 3 years before the prostate cancer diagnosis) apart from non-melanoma skin malignancies;
No ability to complete questionnaires about QoL;
Presence of mental diseases that cannot ensure valid informed consent;
Clareo Health | Radioablation With or Without Androgen DeprIvation Therapy in Metachronous Prostate Cancer OligometaStAsis
